Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | El-Damasy, Ashraf K. | - |
dc.contributor.author | Jin, Heewon | - |
dc.contributor.author | Sabry, Mohamed A. | - |
dc.contributor.author | Kim, Hyun Ji | - |
dc.contributor.author | Alanazi, Mohammed M. | - |
dc.contributor.author | Seo, Seon Hee | - |
dc.contributor.author | Bang, Eun-Kyoung | - |
dc.contributor.author | Keum, Gyochang | - |
dc.date.accessioned | 2024-01-19T09:30:39Z | - |
dc.date.available | 2024-01-19T09:30:39Z | - |
dc.date.created | 2023-07-20 | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1010-660X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/113637 | - |
dc.description.abstract | A new series of 3,4,5-trimethoxyphenyl thiazole pyrimidines has been synthesized and biologically evaluated for its in vitro anticancer activity. Compounds 4a, 4b, and 4h with substituted piperazine showed the best antiproliferative activity. In the NCI-60 cell line screening, compound 4b showed promising cytostatic activity against multiple cell lines. Notably, it elicited a GI value of 86.28% against the NSCL cancer cell line HOP-92 at a 10 & mu;M dose. Compounds 4a and 4h at 10 & mu;M showed promising GI values of 40.87% and 46.14% against HCT-116 colorectal carcinoma and SK-BR-3 breast cancer cell lines, respectively. ADME-Tox prediction of compounds 4a, 4b, and 4h revealed their acceptable drug-likeness properties. In addition, compounds 4a, 4b, and 4h showed a high probability of targeting kinase receptors via Molinspiration and Swiss TargetPrediction. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.title | Design and Synthesis of New 4-(3,4,5-Trimethoxyphenyl)Thiazole-Pyrimidine Derivatives as Potential Antiproliferative Agents | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/medicina59061076 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Medicina (Kaunas, Lithuania), v.59, no.6 | - |
dc.citation.title | Medicina (Kaunas, Lithuania) | - |
dc.citation.volume | 59 | - |
dc.citation.number | 6 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 001017150600001 | - |
dc.identifier.scopusid | 2-s2.0-85163747478 | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordAuthor | trimethoxyphenyl | - |
dc.subject.keywordAuthor | thiazole | - |
dc.subject.keywordAuthor | pyrimidines | - |
dc.subject.keywordAuthor | NCI-60 screening | - |
dc.subject.keywordAuthor | NSCL cancer cell line | - |
dc.subject.keywordAuthor | ADME-Tox prediction | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.